Ra Capital Management, L.P. - Mar 5, 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
JANX
Transactions as of
Mar 5, 2025
Transactions value $
$25,342,965
Form type
4
Date filed
3/7/2025, 06:05 PM
Previous filing
Feb 21, 2025
Next filing
Mar 17, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Purchase $9.3M +304K +3.27% $30.56 9.62M Mar 5, 2025 See footnotes F1, F2, F3
transaction JANX Common Stock Purchase $1.17M +37.5K +0.39% $31.30 9.66M Mar 5, 2025 See footnotes F2, F3, F4
transaction JANX Common Stock Purchase $11.5M +372K +3.85% $30.78 10M Mar 6, 2025 See footnotes F2, F3, F5
transaction JANX Common Stock Purchase $3.42M +110K +1.1% $31.02 10.1M Mar 7, 2025 See footnotes F2, F3, F6
holding JANX Common Stock 1.05M Mar 5, 2025 See footnotes F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.90 to $30.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F3 Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.90 to $31.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.54 to $31.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.74 to $31.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F7 Held directly by the Nexus Fund II.

Remarks:

Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.